U.S. markets closed
  • S&P Futures

    3,833.50
    -0.50 (-0.01%)
     
  • Dow Futures

    30,927.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    11,812.00
    +3.50 (+0.03%)
     
  • Russell 2000 Futures

    1,740.40
    -1.30 (-0.07%)
     
  • Crude Oil

    101.48
    +1.98 (+1.99%)
     
  • Gold

    1,767.70
    +3.80 (+0.22%)
     
  • Silver

    19.18
    +0.06 (+0.33%)
     
  • EUR/USD

    1.0269
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    2.8090
    -0.0800 (-2.77%)
     
  • Vix

    27.54
    +0.01 (+0.04%)
     
  • GBP/USD

    1.1964
    +0.0012 (+0.10%)
     
  • USD/JPY

    135.6900
    -0.1520 (-0.11%)
     
  • BTC-USD

    20,322.44
    -43.52 (-0.21%)
     
  • CMC Crypto 200

    439.70
    -0.32 (-0.07%)
     
  • FTSE 100

    7,025.47
    -207.18 (-2.86%)
     
  • Nikkei 225

    26,172.50
    -250.97 (-0.95%)
     

Altamira's Drug-Free Nasal Spray Shows Benefit In House Dust Mite Study

·1 min read
  • Altamira Therapeutics Ltd (NASDAQ: CYTOannounced topline data from its clinical trial with Bentrio nasal spray in house dust mite (HDM) allergic rhinitis.

  • The HDM challenge trial demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls and good tolerability and safety.

  • Bentrio is a drug-free nasal spray intended for personal protection against airborne viruses and allergens with a triple mode of action.

  • At a single Canadian study site, the trial enrolled 37 patients.

  • Read Next: Why Are Altamira Therapeutics Shares Gaining Today?

  • Under Bentrio treatment, the mean Total Nasal Symptom Score (TNSS) was 4.1 points vs. 5.2 points under no treatment.

  • The changes in TNSS started to separate at the 40-minute time point and, on average, reached 1.5 to 2 points from the mid-point to the end of the exposure.

  • The protective effect was observed with a single or double puff per nostril with no meaningful difference between the two treatment approaches.

  • Regarding safety, there were only a few adverse events, mostly mild, and more than 85% of study participants rated the tolerability of Bentrio as "good" or "very good."

  • Price Action: CYTO shares are up 9.39% at $0.94 during the market session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.